Navigation Links
Ceregene Completes Enrollment of Phase 2 Clinical Trial for Parkinson's Disease
Date:11/14/2007

SAN DIEGO, Nov. 14 /PRNewswire-FirstCall/ -- Ceregene, Inc. today announced that the company has completed enrollment of its randomized, controlled, double-blind, Phase 2 clinical trial evaluating CERE-120, a gene therapy product in development for the treatment of Parkinson's disease. The trial enrolled 58 patients with advanced Parkinson's disease across nine medical centers in the United States. The company expects to announce results from the trial in late 2008. CERE-120 is designed to deliver the neurturin gene, a nervous system growth factor with the ability to maintain the growth and normal function of dopamine-producing neurons which deteriorate in Parkinson's disease.

The Phase 2 trial, which was supported in part by The Michael J. Fox Foundation for Parkinson's Research, was prompted by positive results from a Phase 1 study of CERE-120 which demonstrated a 36 percent (p<0.001) reduction in Parkinson's symptoms at 12 months after administration, as measured by the Unified Parkinson's Disease Rating Scale (UPDRS) motor "off" score ("motor off" meaning patients were off Parkinson's medication at evaluation time). CERE-120 was also shown to be well tolerated in the Phase 1 study. The Phase 2 study was designed to confirm these findings in a controlled trial by randomly assigning patients to receive either CERE-120 or a control treatment at a 2 to 1 ratio and is powered at 90 percent to demonstrate clinical efficacy. The patients in this Phase 2 study will be followed for 12 months for safety and efficacy.

"Completing full enrollment of this multi-center controlled trial represents an important milestone in CERE-120's development as well as in the development of Ceregene as an emerging biotechnology company," stated Jeffrey M. Ostrove, Ph.D., president and chief executive officer of Ceregene. "We are encouraged by the positive results from our Phase 1 trial and carefully designed this Phase 2 study as a controlled trial to confirm those resul
'/>"/>

SOURCE Ceregene, Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine news :

1. Eligard(R) six-month formulation successfully completes European approval procedure
2. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
3. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
4. Symmetry Medical Completes Acquisition Of Specialty Surgical Instruments
5. GSI Securitization Completes Merger and Domicile Transfer
6. Medical Services International Inc. Completes Testing for European Union (EU) Application
7. Inverness Completes Acquisition of Cholestech
8. Billians HealthDATA Completes Comprehensive Long Term Care Database Update
9. Synova Completes Sale of $3.3 Million in Senior Convertible Notes and Warrants
10. Explorer completes the map ... for the bodys blueprint
11. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)NEW YORK, Dec. 4 Thousands of KPMG LLP employees came together in more than 90 offices nationwide today, to participate in a community service event which combines the audit, tax and advisory firm,s
(Date:12/4/2009)WASHINGTON, Dec. 4 The American Association of Homes and Services for the Aging (AAHSA) applauds the Senate for ensuring that the Community Living and Supportive Services (CLASS) provisions remain i
(Date:12/4/2009)MADISON HEIGHTS, Mich., Dec. 4 The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Allergan, Inc. (NYSE: AGN ) as its February 2010 "Stock to Stud
(Date:12/4/2009)WASHINGTON, Dec. 4 In response to the U.S. Justice Department Drug Enforcement Agency,s (DEA) classification of boldione, desoxymethyltestosterone, and 19-nor-4,9(10)-androstadienedione as "anabolic
(Date:12/4/2009)Working with mice, scientists at Johns Hopkins publishing in the December issue of Neoplasia have shown that a protein made by a gene called "Twist" may be the proverbial red flag that can accuratel
Breaking Medicine News(10 mins):Health News:KPMG Employees Provide 'Holiday Bear Hugs' and Books in Firmwide Service Day for Children 2Health News:BetterInvesting Magazine Releases February Stock to Study and Undervalued Stock Choicesfor Investors' Informational and Educational Use 2Health News:Natural Products Association Issues Statement on DEA's Steroid Classification Action 2Health News:Potential new 'twist' in breast cancer detection 2Health News:Potential new 'twist' in breast cancer detection 3
...ct. 1 Sunnylife Global, Inc.,(Pink Sheets: SNYL) ...ns,and financial public relations services. At a ... quality,healthcare management in China and build ...We are thrilled to have been retained to represent...
...J., Oct. 1 Wedgewood Pharmacy and Midwest,Veterin...gency agreement,through which Midwest will represe...000 veterinary clinics in 27 states. The relations...gewood,s compounding services will,be offered to v...
...Oct. 1 In honor of Hispanic Heritage,Month in the...speakers,worldwide, the International Hyperhidrosi...version of its popular patient education brochure.... speak at,the 21st World Congress of Dermatology o...
...chultz Investigates the "Social Brain" in Children...ILADELPHIA, Oct. 1 An internationally,prominent e...ts with,autism, Robert T. Schultz, Ph.D., is joini... Most recently the director of the Yale Developmen...
..., Oct. 1 Merlyn Medical has announced,receipt of ...id warmer that,requires neither battery nor electr...2007 EMS Expo in Orlando, FL, October 11-13 and th...ation vehicles, field use, rescue, or other applic...
...est Distributors and Pharmacy Chains to Carry RESP...evice, NEW YORK and MAROOCHYDORE, Australia, Oct....hat its RESPeRATE(R) hypertension,treatment device... marketing and distribution partner, High Tech,Hea...
Other Medicine News:Health News:Sunnylife Global Retains The Blaine Group For Investor Relations, Financial Public Relations 2Health News:Wedgewood Pharmacy and Midwest Veterinary Supply Sign New Agency Agreement 2Health News:Wedgewood Pharmacy and Midwest Veterinary Supply Sign New Agency Agreement 3Health News:In Honor of Hispanic Heritage Month and Spanish Speakers Worldwide International Hyperhidrosis Society Publishes Important New Patient Booklet in Spanish 2Health News:Brain Imaging Expert Recruited to Study Autism at The Children's Hospital of Philadelphia 2Health News:Brain Imaging Expert Recruited to Study Autism at The Children's Hospital of Philadelphia 3Health News:Merlyn Medical Announces FDA Approval for FlexWarmer in a Joint Agreement with Elltec and Suzuken 2Health News:InterCure and High Tech Health Announce RESPeRATE Launch into Pharmacy Market in Australia 2Health News:InterCure and High Tech Health Announce RESPeRATE Launch into Pharmacy Market in Australia 3Health News:InterCure and High Tech Health Announce RESPeRATE Launch into Pharmacy Market in Australia 4
(Date:12/4/2009)BILLERICA, Mass., Dec. 4 Axsun Technologies, Inc., a wholly-owned subsidiary of Volcano Corporation (Nasdaq: VOLC ), today announced the initial development and successful testing of a novel integra
(Date:12/4/2009)TARRYTOWN, N.Y., Dec. 4 Bayer Diabetes Care today announced the three grand prize winners of Bayer,s "Express Your Simple Win Creativity Contest." Nick Jonas, of the Jonas Brothers, selected the winn
(Date:12/4/2009)WILMINGTON, Del., Dec. 4 AstraZeneca (NYSE: AZN ) today announced that the US Food and Drug Administration (FDA) has approved once-daily SEROQUEL XR® (quetiapine fumarate) Extended Release Tab
Breaking Medicine Technology:Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 2Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 3Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 4Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 5Bayer 'Express Your Simple Win Creativity Contest' Grand Prize Winners Announced 2Bayer 'Express Your Simple Win Creativity Contest' Grand Prize Winners Announced 3US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 2US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 3US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 4US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 5US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 6US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 7US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 8US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 9Researchers Propose Improved Cervical Cancer Screening 57807 1Researchers Propose Improved Cervical Cancer Screening 57807 2Nanoresearchers challenge dogma in protein transportation in cells 10001 1Nanoresearchers challenge dogma in protein transportation in cells 10001 2American Lung Association of Arizona Kicks Off 2009 2010 Influenza Season In Phoenix 57802 1American Lung Association of Arizona Kicks Off 2009 2010 Influenza Season In Phoenix 57802 2American Lung Association of Arizona Kicks Off 2009 2010 Influenza Season In Phoenix 57802 3American Lung Association of Arizona Kicks Off 2009 2010 Influenza Season In Phoenix 57802 4American Lung Association of Arizona Kicks Off 2009 2010 Influenza Season In Phoenix 57802 5
...ounces a $50,000 Grant from,Verizon to help preven...HILADELPHIA, Feb. 7 The Center for Injury,Researc...ladelphia is,pleased to announce a $50,000 grant r...children after an injury. Researchers at the Cente...lies to develop effective,screening tools and inte...
...ologies, Inc. (Nasdaq: EMIS ) announced today tha... concept that absorption of oral vitamin,B12 using...s 15-30 times,greater than with the same dose of o...igen(R) technology is the basis of the company,s u...es and pharmaceutical compounds., "This data demo...
Other Medicine Technology:Helping Families Cope After an Injury 2Emisphere Technologies Announces Positive Results From Animal Studies on Oral B12 Using eligen(R) Technology 2Emisphere Technologies Announces Positive Results From Animal Studies on Oral B12 Using eligen(R) Technology 3
Gibco Penicillin-Streptomycin liquid
Gibco Antibiotic-Antimycotic (100X), liquid
Gentamicin, 50 mg/ml
GENTAMICIN SULFATE, 1000X
Medicine Products: